Cardiovascular safety of lumiracoxib: A meta-analysis of all randomized controlled trials ≥1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis

This publication has 26 references indexed in Scilit:

• Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib
  Current Medical Research and Opinion, 2005
• Efficacy and tolerability of lumiracoxib in the treatmentof osteoarthritis of the knee: A 13-week, randomized, double-blind comparison with celecoxib and placebo
  Clinical Therapeutics, 2005
• Parecoxib, Valdecoxib, and Cardiovascular Risk
  Circulation, 2005
• Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
  The Lancet, 2004
• Coxibs and Cardiovascular Disease
  New England Journal of Medicine, 2004
• Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: A phase II, four‐week, multicenter, randomized, double‐blind, placebo‐controlled trial
  Arthritis Care & Research, 2004
• Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial
  The Lancet, 2004
• Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial
  The Lancet, 2004
• PHARMACOKINETICS AND METABOLISM OF LUMIRACOXIB IN HEALTHY MALE SUBJECTS
  Drug Metabolism and Disposition, 2004
• Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis
  Alimentary Pharmacology & Therapeutics, 2004